In recent years, organ transplantation in the United States has seen a significant increase, largely driven by a donation pathway known as donation after circulatory death (DCD). This method allows organs to be donated from individuals who are dying but not brain dead, significantly expanding the pool of available organs and saving lives. However, the expansion of DCD has also introduced complex ethical questions and procedural challenges at the intersection of life and death.
A Shift in Organ Donation
Traditionally, most transplanted organs came from donors declared brain dead, a rare condition where the brain has irreversibly ceased functioning, but machines keep the heart beating and organs oxygenated. This process allowed ample time for transplant teams to coordinate.
Emily Hoffman, a 34-year-old who died in February 2023 after a traffic accident, exemplifies the shift. Despite severe brain injury, she did not meet the criteria for brain death. Her family, knowing she was a registered organ donor, consented to donation after ventilator support was removed and her heart stopped. Hoffman's case is representative of a growing trend: DCD donors, who account for nearly half of all deceased organ donors in the U.S. today. In 2000, DCD donors provided 219 organs; by 2025, this number had risen to approximately 17,000.
This increase is attributed to technological advancements, such as machines that preserve organs outside the body by circulating warm, oxygenated blood, and policy changes aimed at improving organ procurement organization (OPO) performance. The desperation for organs, driven by a high demand and limited supply, has also propelled the adoption of DCD, making it a more common pathway for donation following catastrophic injuries.
Navigating the Delicate Interval
The DCD process differs from brain death donation in a critical aspect: the timeline. In DCD, death is declared after circulation and heartbeat cease. Because organs begin to deteriorate rapidly once circulation stops, the complex process of organ recovery—testing, matching, and surgical team deployment—must begin after a family decides to withdraw life support but before death has officially occurred.
This narrow interval creates a unique medical situation where one team cares for the dying patient while another prepares for organ recovery. Strict protocols are in place to maintain a firewall between the decision to withdraw life support and the consideration of organ donation, ensuring that the need for organs does not influence end-of-life care decisions. "Ethically, you want to make sure that those two are uncoupled," said Wade Smith, director of the Neurovascular Service at the University of California San Francisco.
New Technologies and Ethical Debates
Recent innovations, particularly normothermic regional perfusion (NRP), have further expanded the possibilities of DCD. NRP techniques restore circulation within the donor's body before organ removal. While abdominal NRP preserves organs below the diaphragm, the more controversial thoracoabdominal NRP restarts the heart, allowing surgeons to assess its viability before recovery.
This reanimation of the heart, even after death has been declared, raises profound ethical questions. Critics argue that restarting circulation, even if measures are taken to prevent blood flow to the brain, blurs the definition of death and could potentially lead to a situation where consciousness might be restored. "There’s a misalignment between NRP practices and the legal standard for how death is defined," said Alexandra Glazier, president of the New England Organ Bank. While proponents emphasize that the heart is restarted solely for organ assessment and not to revive the person, the debate continues.
Patchwork Standards and Patient Safety
The operational standards for DCD also vary significantly across different hospitals and OPOs nationwide. This inconsistency can affect how families are informed, the procedures followed before death, and the authority to pause or halt the donation process if concerns arise. Federal pressure on OPOs to increase organ recovery rates, while intended to improve efficiency, has also led to perceptions of increased aggressiveness by some organizations.
An investigation by the Health Resources and Services Administration (HRSA) in March 2025 highlighted potential systemic failures, documenting issues such as missed vital signs, poor collaboration with medical teams, and inadequate data documentation in certain DCD cases. Federal agencies have since taken steps to address these gaps, including clearer family education and improved reporting channels for misconduct.
The rise of DCD represents a significant advancement in transplantation, offering hope to thousands awaiting organs. However, its continued success hinges on maintaining public trust and ensuring that the process rigorously safeguards the interests of dying patients and their families, while upholding the delicate boundary between life and death.